# Safety and Performance of DKL Crosslinked Sodium Hyaluronate 23 Dermal Filler for Improvement of NLF Appearance

> **NCT05021913** · NA · COMPLETED · sponsor: **Dr. Korman Laboratories Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Aging, Premature

## Interventions

- **DEVICE:** DKL crosslinked sodium hyaluronate 23
- **DEVICE:** Juvéderm Volift™ with lidocaine (Allergan, Inc)

## Key facts

- **NCT ID:** NCT05021913
- **Lead sponsor:** Dr. Korman Laboratories Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-20
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-01-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05021913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05021913, "Safety and Performance of DKL Crosslinked Sodium Hyaluronate 23 Dermal Filler for Improvement of NLF Appearance". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05021913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*